Characterization of clinical blood isolates of Streptococcus agalactiae with reduced susceptibility to levofloxacin

Journal of Chemotherapy

Volumn 21, Issue 4, 2009, Pages 463-464

  Llaneza, E ^a   Seral García, Cristina ^a   Castillo, F J ^a   Duran E ^a   Rubio Calvo, C ^a   Gomez Lus R ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MACROLIDE; NORFLOXACIN; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ADULT; AGGLUTINATION TEST; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CASE REPORT; CELLULITIS; CONCENTRATION RESPONSE; DIABETIC FOOT; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN ALLERGY; POLYMERASE CHAIN REACTION; RECURRENT INFECTION; SEROTYPE; SEROTYPING; STREPTOCOCCUS AGALACTIAE; URINARY TRACT INFECTION;

EID: 70349213334     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.4.463     Document Type: Letter

References (11)

1. Shuchat A. Group B streptococcus. Lancet 1999; 353:51-56.
2. Heelan JS, Hasenbein ME, McAdam AJ. Resistance of group B Streptococcus to selected antibiotics, including erythromycin and clindamycin. J Clin Microbiol 2004; 42:1263-1264.
3. Kawamura Y, Fujiwara H, Mishima N et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother 2003; 47:3605-3609. (Pubitemid 37345728)
4. Wehbeh W, Rojas-Diaz R, Li X et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother 2005; 49:2495-2497. (Pubitemid 40734486)
5. Wu HM, Janapatla RP, Ho YR, Hung KH, Wu CW, Yan JJ, Wu JJ. Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan. Antimicrob Agents Chemother 2008; 52: 1880-1890.
6. Miro E, Rebollo M, Rivera A et al. Streptococcus agalactiae highly resistant to fluoroquinolones. Enferm Infecc Microbiol Clin 2006; 24:562-563. (Pubitemid 44862165)
7. Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: approved standard. 7th ed. CLSI document M7-A7. Clinical Laboratory Standards Institute, Wayne, P.A, 2006.
8. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 18th informational supplement. CLSI document M100-S18. Clinical Laboratory Standards Institute, Wayne, P.A, 2008.
9. Rivera A, Rebollo M, Sanchez F et al. Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain. Clin Microbiol Infect 2005; 11:759-761. (Pubitemid 41167343)
10. Tazi A, Gueudet T, Varon E et al. Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis. Emerg Infect Dis 2008; 14:349-350. (Pubitemid 351213700)
11. Perez-Trallero E, Marimon JM, Gonzalez A et al. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41:560-564.